42352-55-6

Basic information

• Product Name: 2-(2'-Oxopyrazin-1'-yl)acetic acid
• Synonyms: 2-(2'-Oxopyrazin-1'-yl)acetic acid;2-(2-oxopyrazin-1(2H)-yl)acetic acid
• CAS NO: 42352-55-6
• Molecular Formula: C₆H₆N₂O₃
• Molecular Weight: 154.12344
• EINECS: -0
• Mol File: 42352-55-6.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 354.8±44.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 3.38±0.10(Predicted)
• CAS DataBase Reference: 2-(2'-Oxopyrazin-1'-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2'-Oxopyrazin-1'-yl)acetic acid(42352-55-6)
• EPA Substance Registry System: 2-(2'-Oxopyrazin-1'-yl)acetic acid(42352-55-6)

Safety Data

• Hazardous Substances Data: 42352-55-6(Hazardous Substances Data)

Usage

Class

Pyrazinecarboxylic acids and derivatives

Appearance

Yellow crystalline powder

Use

Building block for the synthesis of various pharmaceuticals and organic compounds

Potential as an anticancer agent

Ability to inhibit cell growth

Other properties

Antioxidant and anti-inflammatory properties

Promising candidate

Development of new drugs for various medical conditions

Upstream product

• 6270-63-9 pyrazin-2(1H)-one 
• 79-11-8 chloroacetic acid 

Relevant articles and documents

Nitrogen heterocyclic ring group substituted amide derivative and application thereof

The invention discloses a nitrogen heterocyclic ring group substituted amide derivative and application thereof, particularly relates to a novel nitrogen heterocyclic ring group substituted amide derivative and a drug composition comprising the compound, and further relates to methods for preparing the compound and the drug composition, and application of the compound and the drug composition to preparation of drugs for treating diseases or symptoms, particularly overactive bladder, excited and mediated by beta 3-adrenergic receptors. The compound and the drug composition can be used for activating the beta 3-adrenergic receptors.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.